Reid J L, Dawson D, Macrae I M
Department of Medicine and Therapeutics, University of Glasgow, Scotland.
Clin Exp Hypertens. 1995 Jan-Feb;17(1-2):399-407. doi: 10.3109/10641969509087080.
Endothelin-1 (ET-1) is a 21 aminoacid peptide with potent vasoconstrictor properties. It is synthesised and released by endothelial cells in both the peripheral and cerebral vasculature and is also localised within neurones in discrete brain areas where it may contribute to the central regulation of blood pressure. We have shown that intracisternal ET-1 in conscious rats induces a marked pressor response that is associated with an intense widespread reduction in cerebral blood flow. Subsequent studies with local application of ET-1 to the middle cerebral artery (MCA) revealed a dose dependent reversible vasoconstriction of the artery that resulted in profound reductions in local cerebral blood flow and the development of cerebral infarction. Thus abluminal application of ET-1 to the MCA offers a simple model of reversible focal cerebral ischaemia in the rat that complements the existing models of permanent MCA occlusion. The ET-1 model will help to provide new insights into the mechanisms of cerebral ischaemia and reperfusion injury, and to evaluate the usefulness of novel strategies of neuroprotection.
内皮素 -1(ET -1)是一种具有强大血管收缩特性的21个氨基酸的肽。它由外周和脑血管系统中的内皮细胞合成并释放,也定位于离散脑区的神经元内,在那里它可能参与血压的中枢调节。我们已经表明,清醒大鼠脑池内注射ET -1会诱导明显的升压反应,这与脑血流量广泛且强烈的减少有关。随后将ET -1局部应用于大脑中动脉(MCA)的研究表明,该动脉出现剂量依赖性的可逆性血管收缩,导致局部脑血流量显著减少并引发脑梗死。因此,将ET -1应用于MCA的血管外膜提供了一种大鼠可逆性局灶性脑缺血的简单模型,它补充了现有的永久性MCA闭塞模型。ET -1模型将有助于深入了解脑缺血和再灌注损伤的机制,并评估新型神经保护策略的有效性。